熱門資訊> 正文
京和麒麟宣布管理层变动
2025-12-11 16:12
- Kyowa Kirin (KYKOF) (KNBWY) appointed Abdul Mullick, Ph.D., as President and CEO effective March 2026.
- This follows a dual CEO/COO leadership model implemented in March 2025, where Mullick served as COO alongside Masashi Miyamoto, Ph.D., marking a transition to the company's first non-Japanese CEO.
- Masashi Miyamoto will transition to Chairman while remaining involved in strategic oversight.
- In his new role as CEO, Mullick will focus on driving execution of the company’s Vision for 2030 in the focus disease areas of Bone/Mineral, Intractable Haematological Diseases/Haemato-Oncology and Rare Diseases.
- Mullick joined the company in 2017 and served as President of the Europe / Middle East / Africa region, based in Marlow, United Kingdom, before relocating to Japan in 2023 to lead the business outside of Japan.
More on Kyowa Kirin Co., Ltd.
- Kura Oncology wins FDA approval for leukemia drug
- Seeking Alpha’s Quant Rating on Kyowa Kirin Co., Ltd.
- Historical earnings data for Kyowa Kirin Co., Ltd.
- Dividend scorecard for Kyowa Kirin Co., Ltd.
- Financial information for Kyowa Kirin Co., Ltd.
推薦文章
美股機會日報 | 凌晨3點！美聯儲將公佈1月貨幣政策會議紀要，納指期貨漲近0.5%；13F大曝光！巴菲特連續三季減持蘋果
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
